U.S. Serial Number: 10/576,331

<u>REMARKS</u>

This communication is in response to the Restriction Requirement mailed on February 16, 2011. Claims 1, 9-14, 47, 70, and 75-80 are currently amended. Claims 8, 44-46, 50-53, 55-59, 61-69, 74, 107, and 108 are canceled. Claim 109 is withdrawn. The amendments add no new matter. The right to prosecute the subject matter of any one of the canceled claims in this or in a subsequent continuation, continuation-in-part, or divisional application is hereby reserved. Upon entry of the amendments, claims 1-7, 9-43, 47-49, 54, 60, 70-73, 75-106, and 109-114 will be pending. Reconsideration of the application is requested in view of the foregoing amendments and following remarks.

I. Restrictions/elections

In the restriction requirement, election of one invention from Groups I-III is required under 35 U.S.C. 121. Applicants hereby elect Group I, claims 1-43, 47-49, 53, 54, 59, 60, 70-106, and 109-114, drawn to a Micrococcineae serine protease polypeptide and compositions thereof. Furthermore, as required under 37 CFR 1.499, Applicants elect the Micrococcineae species SEQ ID NO:8 and the composition type as a cleaning composition.

Applicants respectfully solicit the Examiner to expedite the prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC819-2-US/B).

Respectfully submitted.

Dated: June 16, 2011

Cawrence B. Kong, Ph.D., J.D.

Reg. No. 49,043

Customer No. 05100 Danisco US Inc. 925 Page Mill Road Palo Alto, CA 94304 Tel: 650-846-7636 Fax: 650-845-6504

GC819-2-US/B Restriction Requirement